Skip to main content

Tardive Dyskinesia

Center of Excellence

Leaders in the field sharing authoritative insights and institutional best practices
VIDEO
Martha Sajatovic, MD, provides details of a study which found that deutetrabenazine was effective as a treatment for tardive dyskinesia both in patients aged less than 55 years and in patients aged 55 years or older.
Q&A
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, shares guidance on the latest research and strategies for treating tardive dyskinesia.
Coping During COVID-19
In this video, psychiatrist Richard Jackson, MD, speaks about assessing and monitoring tardive dyskinesia during telepsychiatry visits.
Coping During COVID-19
In this video, Leslie Citrome, MD, MPH, details 5 steps to success for clinicians treating patients who have tardive dyskinesia or are at risk of the disorder.
Coping During COVID-19
In this video, Psych Congress Steering Committee member Rakesh Jain, MD, MPH, offers guidance on the proper treatment of tardive dyskinesia (TD) during the COVID-19 pandemic.
BLOG
BLOG: A recent experience showed me that seeing tardive dyskinesia (TD) can be hard, even for people who have made a commitment to look for it.
YOUR QUESTIONS ANSWERED
Is there any rationale for using both deutetrabenazine (Austedo) and valbenazine (Ingrezza) at the same time? Find out from Psych Congress cochair Rakesh Jain, MD, MPH.
YOUR QUESTIONS ANSWERED
Is there benefit in treating a patient with a VMAT2 inhibitor if they have already had severe tardive dyskinesia for several years? Find out here.
VIDEO
Joseph P. McEvoy, MD, discusses new strategies for treating tardive dyskinesia. Dr. McEvoy is Professor of Psychiatry and Health Behavior and the I. Clark Case Chair in Psychotic Disorders at the Medical College of Georgia.
Back to Top